136 related articles for article (PubMed ID: 28012793)
1. PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
van Loon J; Even AJG; Aerts HJWL; Öllers M; Hoebers F; van Elmpt W; Dubois L; Dingemans AC; Lalisang RI; Kempers P; Brans B; Winnepenninckx V; Speel EJ; Thunnissen E; Smits KM; Boellaard R; Vugts DJ; De Ruysscher D; Lambin P
Radiother Oncol; 2017 Feb; 122(2):267-273. PubMed ID: 28012793
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.
Even AJ; Hamming-Vrieze O; van Elmpt W; Winnepenninckx VJ; Heukelom J; Tesselaar ME; Vogel WV; Hoeben A; Zegers CM; Vugts DJ; van Dongen GA; Bartelink H; Mottaghy FM; Hoebers F; Lambin P
Oncotarget; 2017 Jan; 8(3):3870-3880. PubMed ID: 27965472
[TBL] [Abstract][Full Text] [Related]
3. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
4.
Miedema IHC; Huisman MC; Zwezerijnen GJC; Grempler R; Pitarch AP; Thiele A; Hesse R; Elgadi M; Peltzer A; Vugts DJ; van Dongen GAMS; de Gruijl TD; Menke-van der Houven van Oordt CW; Bahce I
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2068-2080. PubMed ID: 36859619
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
6. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
[TBL] [Abstract][Full Text] [Related]
7. Validation of simplified uptake measures against dynamic Patlak K
Wijngaarden JE; Huisman MC; Jauw YWS; van Dongen GAMS; Greuter HNJM; Schuit RC; Cleveland M; Gootjes EC; Vugts DJ; Menke-van der Houven van Oordt CW; Boellaard R
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1897-1905. PubMed ID: 36820891
[TBL] [Abstract][Full Text] [Related]
8. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
9. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
[TBL] [Abstract][Full Text] [Related]
10. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study.
Hughes S; Liong J; Miah A; Ahmad S; Leslie M; Harper P; Prendiville J; Shamash J; Subramaniam R; Gaya A; Spicer J; Landau D
J Thorac Oncol; 2008 Jun; 3(6):648-51. PubMed ID: 18520806
[TBL] [Abstract][Full Text] [Related]
11.
Jauw YWS; O'Donoghue JA; Zijlstra JM; Hoekstra OS; Menke-van der Houven van Oordt CW; Morschhauser F; Carrasquillo JA; Zweegman S; Pandit-Taskar N; Lammertsma AA; van Dongen GAMS; Boellaard R; Weber WA; Huisman MC
J Nucl Med; 2019 Dec; 60(12):1825-1832. PubMed ID: 31147401
[No Abstract] [Full Text] [Related]
12. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
13. Validation of simplified dosimetry approaches in ⁸⁹Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses.
Makris NE; van Velden FH; Huisman MC; Menke CW; Lammertsma AA; Boellaard R
Med Phys; 2014 Oct; 41(10):102503. PubMed ID: 25281978
[TBL] [Abstract][Full Text] [Related]
14. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
16. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
18. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.
Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H
Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030
[TBL] [Abstract][Full Text] [Related]
19.
Kok IC; Hooiveld JS; van de Donk PP; Giesen D; van der Veen EL; Lub-de Hooge MN; Brouwers AH; Hiltermann TJN; van der Wekken AJ; Hijmering-Kappelle LBM; Timens W; Elias SG; Hospers GAP; Groen HJM; Uyterlinde W; van der Hiel B; Haanen JB; de Groot DJA; Jalving M; de Vries EGE
Ann Oncol; 2022 Jan; 33(1):80-88. PubMed ID: 34736925
[TBL] [Abstract][Full Text] [Related]
20. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
